Tags

Type your tag names separated by a space and hit enter

Evidence of specificity in the action of angiogenesis antagonists.
Int J Microcirc Clin Exp. 1994 Jul-Aug; 14(4):226-32.IJ

Abstract

It is not known whether each type of angiogenesis reaction has a specific antiangiogenic mechanism and to what extent angiostatic agents can exert additional or synergistic effects. The objective of this study was to elucidate the way in which systemic angiostatic drug treatment by either one drug at a time or two in combination affects distinct angiogenesis reactions in one and the same vascular bed. The chemically unrelated drugs which were used were dexamethasone (DE) and ciclosporin A (CS) at nontoxic doses in the range used clinically. These drugs are known to act angiostatically in the rat. The rat mesenteric window angiogenesis assay was used to assess the systemic effect of DE, CS and DE plus CS in saline-mediated angiogenesis (SMA) and mast-cell-mediated angiogenesis (MCMA). Angiogenesis was quantified by microscopic and morphometric means, one variable being the number of vessel profiles per unit tissue length (No/UL), a measure related to the degree of microvascular branching and tortuosity. Whereas CS significantly suppressed No/UL in SMA without substantially affecting MCMA, DE plus CS significantly suppressed No/UL in MCMA, but, unexpectedly, somewhat increased No/UL in SMA. As compared with either drug given alone, the coadministration of the drugs clearly did not enhance the antiangiogenic effect in SMA. The drugs, whether alone or in combination specifically and selectively suppressed the angiogenesis reactions which were examined, thereby suggesting distinct antiangiogenic mechanisms in SMA and MCMA.

Authors+Show Affiliations

Department of Pathology, University of Göteborg, Sahlgrenska University Hospital, Sweden.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7531674

Citation

Norrby, K. "Evidence of Specificity in the Action of Angiogenesis Antagonists." International Journal of Microcirculation, Clinical and Experimental, vol. 14, no. 4, 1994, pp. 226-32.
Norrby K. Evidence of specificity in the action of angiogenesis antagonists. Int J Microcirc Clin Exp. 1994;14(4):226-32.
Norrby, K. (1994). Evidence of specificity in the action of angiogenesis antagonists. International Journal of Microcirculation, Clinical and Experimental, 14(4), 226-32.
Norrby K. Evidence of Specificity in the Action of Angiogenesis Antagonists. Int J Microcirc Clin Exp. 1994 Jul-Aug;14(4):226-32. PubMed PMID: 7531674.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence of specificity in the action of angiogenesis antagonists. A1 - Norrby,K, PY - 1994/7/1/pubmed PY - 1994/7/1/medline PY - 1994/7/1/entrez SP - 226 EP - 32 JF - International journal of microcirculation, clinical and experimental JO - Int J Microcirc Clin Exp VL - 14 IS - 4 N2 - It is not known whether each type of angiogenesis reaction has a specific antiangiogenic mechanism and to what extent angiostatic agents can exert additional or synergistic effects. The objective of this study was to elucidate the way in which systemic angiostatic drug treatment by either one drug at a time or two in combination affects distinct angiogenesis reactions in one and the same vascular bed. The chemically unrelated drugs which were used were dexamethasone (DE) and ciclosporin A (CS) at nontoxic doses in the range used clinically. These drugs are known to act angiostatically in the rat. The rat mesenteric window angiogenesis assay was used to assess the systemic effect of DE, CS and DE plus CS in saline-mediated angiogenesis (SMA) and mast-cell-mediated angiogenesis (MCMA). Angiogenesis was quantified by microscopic and morphometric means, one variable being the number of vessel profiles per unit tissue length (No/UL), a measure related to the degree of microvascular branching and tortuosity. Whereas CS significantly suppressed No/UL in SMA without substantially affecting MCMA, DE plus CS significantly suppressed No/UL in MCMA, but, unexpectedly, somewhat increased No/UL in SMA. As compared with either drug given alone, the coadministration of the drugs clearly did not enhance the antiangiogenic effect in SMA. The drugs, whether alone or in combination specifically and selectively suppressed the angiogenesis reactions which were examined, thereby suggesting distinct antiangiogenic mechanisms in SMA and MCMA. SN - 0167-6865 UR - https://www.unboundmedicine.com/medline/citation/7531674/Evidence_of_specificity_in_the_action_of_angiogenesis_antagonists_ DB - PRIME DP - Unbound Medicine ER -